CTLA4 and cancer: The fact that anti-CTLA-4 antibodies are capable to induce long-term immunity in cancer patients demonstrates that CTLA-4 remains an important immunotherapy target.355,356 Nevertheless, CTLA-4-targeting inhibitors have not reached its full potential, as evidenced by high rates of immunotherapy-related adverse effects (irAEs) and relatively low response rates.